Plasma microparticles from patients with systemic lupus erythematosus modulate the content of miRNAs in U937 cells

Liseth Carmona-Pérez1, Mauricio Rojas1,2, Carlos Muñoz-Vahos3,4

  • 1Grupo de Inmunología Celular e Inmunogenética (GICIG), Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia (UDEA), Medellín, Colombia.

Immunology
|May 18, 2021
PubMed

Insights

Systemic lupus erythematosus (SLE) patients have increased microparticles (MPs) containing altered microRNAs (miRNAs). These SLE MPs modulate immune cell responses, suggesting a role in disease pathogenesis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Reduced clearance of apoptotic cells and microparticles (MPs) is characteristic of systemic lupus erythematosus (SLE).
  • MPs can carry immune-modulating molecules, influencing disease processes.
  • Specific microRNAs (miRNAs), miR-126 and miR-146a, are implicated in immune regulation.

Purpose of the Study:

  • To investigate the presence and levels of miR-126 and miR-146a within plasma MPs from SLE patients.
  • To analyze the functional capacity of SLE-derived MPs in modulating immune cell responses using the U937 cell line.

Main Methods:

  • Isolation and characterization of circulating MPs from plasma of healthy controls (HCs), SLE patients, and patients with other autoimmune diseases (OAD) using flow cytometry.
  • Quantification of miR-126 and miR-146a content in MPs via RT-qPCR.
  • Incubation of U937 cells with isolated MPs to assess changes in cell phenotype, cytokine expression, miRNA levels, and IRF5 expression.

Main Results:

  • Active SLE patients exhibited higher plasma MP concentrations, correlating with SLE Disease Activity Index (SLEDAI) scores.
  • CD14+ MPs were significantly more abundant in SLE patients compared to HCs.
  • SLE MPs showed decreased miR-146a and increased miR-126 levels, with miR-126 positively correlating with SLEDAI.
  • MP treatment of U937 cells altered immune marker expression (HLA-DR, CD18, CD119), increased pro-inflammatory cytokines (IL-6, TNF-α, IL-8), and modified intracellular miRNA levels, but not IRF5.

Conclusions:

  • Plasma MPs, particularly those from SLE patients, are altered in miRNA content and can modulate immune cell behavior.
  • These findings highlight a potential role for SLE-derived MPs and their miRNA cargo in the immune dysregulation observed in SLE.
  • Further research into SLE MPs could reveal novel diagnostic or therapeutic targets.